Vetera Gold XP Vaccine

VETERA^® GOLD XP + VEE is an equine influenza Florida sublineage (clade 1 and clade 2), herpes (EHV 1 and 4), Eastern, Western and Venezuelan encephalomyelitis, West Nile Virus, tetanus vaccine.

NOTICE: This item requires Express shipping due to the perishable nature of this product. Express orders are shipped Monday-Wednesday. Cannot be shipped to a PO Box. Product can only be shipped to the continental US.

Features
Includes a unique North American Equine E159^TM West Nile Virus strain
Includes Florida sublineage clade 1 (OH/03), Florida sublineage clade 2 (RI/07) and Kentucky lineage (KY/95) equine influenza strains as recommended by the Expert Surveillance Panel on Equine Influenza (OIE)
At least 12-month WNV and 6-month (OH/03) equine influenza DOI
Unique 8-way protection in one vaccine
Contains both EHV-1 and EHV-4 antigens
Incorporates the Carbimmune® adjuvant formulation
Ultrafil® purification technology
Safe for use in horses as young as 4 months of age
Proven safe in pregnant mares

Advantages

VETERA GOLD XP + VEE protects against EIV, EHV (EHV-1 and EHV-4), EEE, WEE, VEE, tetanus and West Nile Virus in a 1 mL dose offering the ultimate in convenience and protection. It incorporates updated influenza strains that include Florida sublineage clade 1 (OH/03), Florida sublineage clade 2 (RI/07) and American lineage (KY/95) influenza strains, as recommended by the Expert Surveillance Panel on Equine Influenza (OIE). It also includes a contemporary West Nile Virus strain that horses are most likely to be exposed to. ULTRAFIL purification process and CARBIMMUNE adjuvant formulation result in a relevant killed vaccine that provides an optimal immune response with minimal reactions.

PRECAUTIONS
This product has been tested under laboratory conditions and shown to meet all federal standards for safety and efficacy in normal, healthy, immunocompetent animals. This level of performance may be affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies, or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.